Rallybio to Speak at Forthcoming Investor Conferences

Rallybio Corporation (Nasdaq: RLYB), based in New Haven, Connecticut, is a biotechnology firm focused on creating groundbreaking therapies for patients suffering from severe and rare diseases. The company has announced its involvement in two upcoming investor conferences.

On September 5, 2024, Rallybio will participate in the 2024 Wells Fargo Healthcare Conference in Everett, Massachusetts. Stephen Uden, M.D., the Chief Executive Officer, is scheduled to take part in a fireside chat at 3:45 p.m. Eastern Time. Following that, on September 10, 2024, Rallybio will be present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. Dr. Uden will deliver a corporate overview at 11:00 a.m. Eastern Time.

Both events will be streamed live and can be accessed via the Events and Presentations section on Rallybio’s official website. The webcasts will remain available for replay for 30 days after each presentation.

Rallybio is dedicated to developing and commercializing treatments that significantly impact the lives of patients with rare and severe diseases. The company’s product pipeline is designed to address critical unmet medical needs, specifically in maternal fetal health, complement dysregulation, hematology, and metabolic disorders. Currently, Rallybio has two programs in clinical stages: RLYB212, an anti-HPA-1a antibody aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, an inhibitor targeting complement component 5 (C5) with potential applications in treating multiple diseases linked to complement dysregulation. Additionally, Rallybio is advancing other programs in preclinical development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!